The Development of Eye Tissues via Human Induced Pluripotent Stem (iPS) Cells.

通过人类诱导多能干 (iPS) 细胞发育眼组织。

基本信息

  • 批准号:
    BB/P017843/1
  • 负责人:
  • 金额:
    $ 93.49万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2018
  • 资助国家:
    英国
  • 起止时间:
    2018 至 无数据
  • 项目状态:
    已结题

项目摘要

The cells that exist in the tissues of our body have specific functions and are adapted to suit the particular tissue that they help form. Skin cells, for example, are different to eye cells, which are different to blood cells. And, of course, each cell type has its own distinctive role. Mature cells, whichever tissue they are in, are what we know as differentiated cells, because they have become adapted to their biological role in the tissue in which they help form. But, during development in the embryo our cells do not have this tissue-specific identity. Indeed, the early cells in embryogenesis can go down different developmental pathways and become different cell types. These early undifferentiated cells are known as stem cells.For a long time, it was accepted that once a cell had "chosen its path" and differentiated into a particular type of cell, it had embarked on an irreversible process. But, in 2012 two scientists were awarded the Nobel Prize in Physiology or Medicine (Sir John Gurdon (Cambridge University, UK) and Prof Shinya Yamanaka (Kyoto University, Japan)) for their research, which showed that differentiated adult cells could be reprogrammed via a manipulation using four genetic factors added to a cell's nucleus - factors that are now known as Yamanaka factors. These reprogrammed cells became an earlier, less differentiated cell, capable of differentiation into a number of cell types. Such cells are called iPS cells -- induced pluripotent stem cells.Our new planned research is based on a discovery made by our collaborators on this proposal in Osaka University, Japan, working with us and with Prof Yamanaka and his team in nearby Kyoto University. It showed that some types of human iPS cells can grow in the laboratory and form a cellular multi-zone, in which cells in different areas resemble cells of different eye tissues; lens, retina, cornea, for example. This discovery is particularly exciting because the cells that most closely resemble a natural corneal epithelium - i.e. the front layer of cells on the eye that support the tear film - can be transplanted onto the eye where they remain functional. This research has a strong future potential for the use of human iPS cells for the treatment of eye disease.In our planned study we will investigate the iPS cells that have formed into eye-like tissue. To do so, we will use powerful 3D electron microscopy technologies that can image the cells at high resolution and at high magnification. We will also use antibodies to specific molecules to see how the iPS cell-derived eye-like cells are communicating with one another, and how we can manipulate these communication pathways using certain chemicals to modulate the formation of eye-like iPS cells. We also have expertise from our previous experiments on cornea and cartilage in understanding how some molecules, called proteoglycans, help keep stem cells to stay stem cells in their niche areas or environments in tissues. In the healthy cornea, for example, we know that various special types of proteoglycans populate an area of the cornea known as the stem cell niche. Basically, this is a region of a tissue that helps support and maintain the stem cells. We will now extract and purify proteoglycans from cornea and chemically modify them using enzymes. The modified proteoglycans will then be used to help grow iPS cell-derived corneal epithelial constructs to understand what types of proteoglycans or cleaved proteoglycan fragments are important to retain cellular "stemness". This will help improve the potential for human iPS cell-derived corneal epithelial cell production for future surgical use. Finally, and importantly, we will examine in detail how iPS cells in our eye-like multi-zone can be used to replicate lens cells, which has the exciting potential of helping the regeneration of lenses in the human eye.
存在于我们身体组织中的细胞具有特定的功能,并适应它们帮助形成的特定组织。例如,皮肤细胞不同于眼细胞,眼细胞不同于血细胞。当然,每种细胞类型都有自己独特的作用。成熟细胞,无论它们在哪个组织中,都是我们所知道的分化细胞,因为它们已经适应了它们在组织中的生物学作用。但是,在胚胎发育过程中,我们的细胞不具有这种组织特异性。事实上,胚胎发生的早期细胞可以沿着不同的发育途径发展,成为不同的细胞类型。这些早期未分化的细胞被称为干细胞。长期以来,人们认为细胞一旦“选择了自己的道路”,分化成某种特定类型的细胞,就开始了一个不可逆的过程。但是,在2012年,两名科学家获得了诺贝尔生理学或医学奖(英国剑桥大学的约翰古尔登爵士和日本京都大学的山中伸弥教授),因为他们的研究表明,通过将四种遗传因子添加到细胞核中,可以对分化的成年细胞进行重新编程-这些因子现在被称为山中因子。这些重编程的细胞成为较早的、分化程度较低的细胞,能够分化成许多细胞类型。这种细胞被称为iPS细胞--诱导多能干细胞。我们新计划的研究是基于我们在日本大坂大学的合作者对这一提议的发现,与我们以及附近京都大学的山中伸弥教授和他的团队合作。它表明某些类型的人类iPS细胞可以在实验室中生长并形成细胞多区,其中不同区域的细胞类似于不同眼组织的细胞;例如,透镜,视网膜,角膜。这一发现特别令人兴奋,因为最接近天然角膜上皮的细胞-即眼睛上支持泪膜的前层细胞-可以移植到眼睛上,在那里它们保持功能。这项研究对人类iPS细胞用于治疗眼部疾病具有强大的未来潜力。在我们计划的研究中,我们将研究已形成眼样组织的iPS细胞。为此,我们将使用强大的3D电子显微镜技术,可以以高分辨率和高放大率对细胞进行成像。我们还将使用针对特定分子的抗体来观察iPS细胞衍生的眼样细胞如何相互通信,以及我们如何使用某些化学物质来操纵这些通信途径以调节眼样iPS细胞的形成。我们还从之前的角膜和软骨实验中获得了专业知识,以了解一些称为蛋白聚糖的分子如何帮助干细胞保持在组织中的利基区域或环境中。例如,在健康的角膜中,我们知道各种特殊类型的蛋白聚糖聚集在角膜的一个称为干细胞龛的区域。基本上,这是组织的一个区域,有助于支持和维持干细胞。我们现在将从角膜中提取和纯化蛋白聚糖,并使用酶对其进行化学修饰。然后,修饰的蛋白聚糖将用于帮助生长iPS细胞衍生的角膜上皮构建体,以了解什么类型的蛋白聚糖或切割的蛋白聚糖片段对于保持细胞的“干性”是重要的。这将有助于提高人类iPS细胞衍生的角膜上皮细胞生产的潜力,用于未来的手术用途。最后,重要的是,我们将详细研究如何在我们的眼睛样多区的iPS细胞可以用来复制透镜细胞,这具有令人兴奋的潜力,帮助再生的晶状体在人类的眼睛。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CD200 facilitates the isolation of corneal epithelial cells derived from human pluripotent stem cells.
  • DOI:
    10.1038/s41598-018-34845-2
  • 发表时间:
    2018-11-08
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Hayashi R;Ishikawa Y;Katayama T;Quantock AJ;Nishida K
  • 通讯作者:
    Nishida K
Chondroitin Sulphate/Dermatan Sulphate Proteoglycans: Potential Regulators of Corneal Stem/Progenitor Cell Phenotype In Vitro.
  • DOI:
    10.3390/ijms24032095
  • 发表时间:
    2023-01-20
  • 期刊:
  • 影响因子:
    5.6
  • 作者:
    Bains, Kiranjit K.;Ashworth, Sean;Koudouna, Elena;Young, Robert D.;Hughes, Clare E.;Quantock, Andrew J.
  • 通讯作者:
    Quantock, Andrew J.
Chondroitin Sulfate as a Potential Modulator of the Stem Cell Niche in Cornea.
  • DOI:
    10.3389/fcell.2020.567358
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Ashworth S;Harrington J;Hammond GM;Bains KK;Koudouna E;Hayes AJ;Ralphs JR;Regini JW;Young RD;Hayashi R;Nishida K;Hughes CE;Quantock AJ
  • 通讯作者:
    Quantock AJ
KLF4 prevents epithelial to mesenchymal transition in human corneal epithelial cells via endogenous TGF-β2 suppression
  • DOI:
    10.1016/j.reth.2019.08.003
  • 发表时间:
    2019-12-01
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Fujimoto, Satoko;Hayashi, Ryuhei;Nishida, Kohji
  • 通讯作者:
    Nishida, Kohji
Cell jamming, stratification and p63 expression in cultivated human corneal epithelial cell sheets
  • DOI:
    10.1038/s41598-020-64394-6
  • 发表时间:
    2020-06-09
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Baba, Koichi;Sasaki, Kei;Nishida, Kohji
  • 通讯作者:
    Nishida, Kohji
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew Quantock其他文献

選択的Rhoキナーゼ阻害剤の角膜実質創傷治癒への影響
选择性Rho激酶抑制剂对角膜基质伤口愈合的影响
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    山本真弓;奥村直毅;上野盛夫;坂本雄二;木下茂;Robert Young;Andrew Quantock;小泉範子
  • 通讯作者:
    小泉範子
角膜内皮の小胞体ストレス応答におけるmitochondria-associated ER membranesの関与
线粒体相关内质网膜参与角膜内皮内质网应激反应
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    松本紗季;奥村直毅;奥田浩和;Robert Young;Andrew Quantock;小泉範子
  • 通讯作者:
    小泉範子

Andrew Quantock的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew Quantock', 18)}}的其他基金

Nanoscale Structural Characterisations of Ocular Tissues Derived from Human iPS Cells
人类 iPS 细胞来源的眼组织的纳米级结构表征
  • 批准号:
    BB/X000966/1
  • 财政年份:
    2023
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
The Genomic Basis of Human Induced Pluripotent Stem (iPS) Cell Differentiation into Eye-Like Tissues.
人类诱导多能干细胞 (iPS) 分化为类眼组织的基因组基础。
  • 批准号:
    BB/S015981/1
  • 财政年份:
    2019
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
Targeted Drug Delivery to the Cornea of the Eye Via Medicated Contact Lenses and Mucoadhesive Thin Films
通过药用隐形眼镜和粘膜粘附薄膜将靶向药物递送至眼角膜
  • 批准号:
    BB/S004874/1
  • 财政年份:
    2019
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
A mechanistic understanding of corneal pathobiology and the development of therapeutic strategies for the treatment of connective tissue disorders
对角膜病理学的机制理解和结缔组织疾病治疗策略的开发
  • 批准号:
    MR/S037829/1
  • 财政年份:
    2019
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
Japan Partnering Award: The Generation of Eye Tissues from Human Induced Pluripotent Stem (iPS) Cells.
日本合作奖:利用人类诱导多能干细胞 (iPS) 生成眼组织。
  • 批准号:
    BB/R021244/1
  • 财政年份:
    2018
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
Targeted Drug Delivery to the Cornea of the Eye Via Thin-Film Slow Release Technology.
通过薄膜缓释技术将靶向药物输送至眼角膜。
  • 批准号:
    BB/N022106/1
  • 财政年份:
    2017
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
A Freedom to Operate Proposal to Research Targeted Drug Delivery to the Cornea of the Eye Via Thin-Film Slow Release Technology.
自由实施研究通过薄膜缓释技术将靶向药物输送到眼角膜的提案。
  • 批准号:
    BB/P011969/1
  • 财政年份:
    2016
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
The Cellular Control of Corneal Development and Transparency and Generation of Biomimetic Corneal Tissue.
角膜发育和透明度的细胞控制以及仿生角膜组织的生成。
  • 批准号:
    BB/M025349/1
  • 财政年份:
    2015
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
A Physical Characterisation of Assembly Mechanisms and Light Transmission in Cornea.
角膜组装机制和光传输的物理表征。
  • 批准号:
    EP/F034970/1
  • 财政年份:
    2008
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant

相似海外基金

The Genomic Basis of Human Induced Pluripotent Stem (iPS) Cell Differentiation into Eye-Like Tissues.
人类诱导多能干细胞 (iPS) 分化为类眼组织的基因组基础。
  • 批准号:
    BB/S015981/1
  • 财政年份:
    2019
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
Japan Partnering Award: The Generation of Eye Tissues from Human Induced Pluripotent Stem (iPS) Cells.
日本合作奖:利用人类诱导多能干细胞 (iPS) 生成眼组织。
  • 批准号:
    BB/R021244/1
  • 财政年份:
    2018
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
Investigating age-dependent regulation of complement in human eye tissues: implications for Age-related Macular Degeneration
研究人眼组织中补体的年龄依赖性调节:对年龄相关性黄斑变性的影响
  • 批准号:
    MR/K004441/1
  • 财政年份:
    2013
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Research Grant
14-3-3?? and epithelial differentiation in the eye and other tissues
14-3-3??
  • 批准号:
    8319328
  • 财政年份:
    2011
  • 资助金额:
    $ 93.49万
  • 项目类别:
14-3-3?? and epithelial differentiation in the eye and other tissues
14-3-3??
  • 批准号:
    8093146
  • 财政年份:
    2011
  • 资助金额:
    $ 93.49万
  • 项目类别:
Enhanced Drug Access to Eye Tissues
增强药物进入眼组织的机会
  • 批准号:
    6787485
  • 财政年份:
    2004
  • 资助金额:
    $ 93.49万
  • 项目类别:
Plasmid Delivery & Expression in Embryonic Eye Tissues
质粒递送
  • 批准号:
    6784231
  • 财政年份:
    2003
  • 资助金额:
    $ 93.49万
  • 项目类别:
Plasmid Delivery & Expression in Embryonic Eye Tissues
质粒递送
  • 批准号:
    6927851
  • 财政年份:
    2003
  • 资助金额:
    $ 93.49万
  • 项目类别:
Plasmid Delivery & Expression in Embryonic Eye Tissues
质粒递送
  • 批准号:
    6680609
  • 财政年份:
    2003
  • 资助金额:
    $ 93.49万
  • 项目类别:
Structural specificities ofiris tissues in the vertebrate eye
脊椎动物眼睛虹膜组织的结构特异性
  • 批准号:
    09470003
  • 财政年份:
    1997
  • 资助金额:
    $ 93.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了